ERBB2 and non-small cell lung carcinoma: Trastuzumab deruxtecan, a humanized anti‐HER2 monoclonal antibody conjugated to a topoisomerase I inhibitor, has been evaluated in patients with metastatic HER2‐mutant NSCLC who were refractory to standard therapies [48].